Anti-PVRIG/ C7orf15/ CD112R monoclonal antibody

Anti-PVRIG/ C7orf15/ CD112R antibody for FACS & in-vivo assay

Target products collectionGo to PVRIG/PVRIG products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T49105-Ab-1/ GM-Tg-hg-T49105-Ab-2Anti-Human PVRIG monoclonal antibodyHuman
GM-Tg-rg-T49105-Ab-1/ GM-Tg-rg-T49105-Ab-2Anti-Rat PVRIG monoclonal antibodyRat
GM-Tg-mg-T49105-Ab-1/ GM-Tg-mg-T49105-Ab-2Anti-Mouse PVRIG monoclonal antibodyMouse
GM-Tg-cynog-T49105-Ab-1/ GM-Tg-cynog-T49105-Ab-2Anti-Cynomolgus/ Rhesus macaque PVRIG monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T49105-Ab-1/ GM-Tg-felg-T49105-Ab-2Anti-Feline PVRIG monoclonal antibodyFeline
GM-Tg-cang-T49105-Ab-1/ GM-Tg-cang-T49105-Ab-2Anti-Canine PVRIG monoclonal antibodyCanine
GM-Tg-bovg-T49105-Ab-1/ GM-Tg-bovg-T49105-Ab-2Anti-Bovine PVRIG monoclonal antibodyBovine
GM-Tg-equg-T49105-Ab-1/ GM-Tg-equg-T49105-Ab-2Anti-Equine PVRIG monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T49105-Ab-1/ GM-Tg-hg-T49105-Ab-2; GM-Tg-rg-T49105-Ab-1/ GM-Tg-rg-T49105-Ab-2;
GM-Tg-mg-T49105-Ab-1/ GM-Tg-mg-T49105-Ab-2; GM-Tg-cynog-T49105-Ab-1/ GM-Tg-cynog-T49105-Ab-2;
GM-Tg-felg-T49105-Ab-1/ GM-Tg-felg-T49105-Ab-2; GM-Tg-cang-T49105-Ab-1/ GM-Tg-cang-T49105-Ab-2;
GM-Tg-bovg-T49105-Ab-1/ GM-Tg-bovg-T49105-Ab-2; GM-Tg-equg-T49105-Ab-1/ GM-Tg-equg-T49105-Ab-2
Products NameAnti-PVRIG monoclonal antibody
Formatmab
Target NamePVRIG
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-PVRIG benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species PVRIG/ C7orf15/ CD112R VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-T49105
    Target NamePVRIG
    Gene ID79037,102640920,680923,711659,608526,101099421,514026,102149166
    Gene Symbol and SynonymsAABR07035561.2,C7orf15,CD112R,Gm36869,PVRIG
    Uniprot AccessionQ6DKI7
    Uniprot Entry NamePVRIG_HUMAN
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target, Immuno-oncology Target
    DiseaseN/A
    Gene EnsemblENSG00000213413
    Target ClassificationCheckpoint-Immuno Oncology

    The target: PVRIG, gene name: PVRIG, also named as C7orf15, CD112R. Enables phosphatase binding activity and signaling receptor activity. Involved in negative regulation of T cell receptor signaling pathway. Located in plasma membrane. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.